



Complement Therapeutics in C3G & IgAN

Registration/Reception Location: Radisson Blu Béke Hotel (Teréz krt. 43., H-1067 Budapest, Hungary)

Forum Location: Radisson Blu Béke Hotel (Teréz krt. 43., H-1067 Budapest, Hungary)

Friday, 2 May 2025

Time

18:00 – 20:00	Registration and Reception
---------------	----------------------------

Saturday, 3 May 2025

Time	Talk Topic	Speaker
9:00 – 9:10	Welcome on behalf of ISN	David Kavanagh and Jonathan Barratt
THE ROLE OF COMPLEMENT IN C3G & IgAN: WHAT WE KNOW AND WHAT WE DON'T KNOW		
<i>Session Moderators:</i>		
9:10 – 9:30	Setting the scene on the landscape of C3G	David Kavanagh
9:30 – 9:50	Setting the scene on the landscape of IgAN	Jonathan Barratt
9:50 – 10:05	Q&A	
MEASURING COMPLEMENT ACTIVITY IN C3G & IgAN: CURRENT PRACTICE & UNMET NEED		
<i>Session Moderators:</i>		
10:05 – 10:25	Complement biomarkers in C3G - do they inform diagnosis treatment strategies?	Richard Smith
10:25 – 10:45	Complement biomarkers in IgAN - do they inform diagnosis treatment strategies?	Peter Garred
10:45 – 11:00	Q&A	
11:00 – 11:30	Coffee Break	
11:30 – 11:50	Can genetic studies inform use of complement therapeutics in C3G	Sophie Chauvet
11:50 – 12:10	Can genetic studies inform use of complement therapeutics in IgAN	Danny Gale
12:10 – 12:25	Q&A	
12:25 – 12:45	Can the kidney biopsy inform use of complement therapeutics in C3G?	Terry Cook
12:45 – 13:05	Can the kidney biopsy inform use of complement therapeutics in IgAN	Ian Roberts
13:05 – 13:20	Q&A	
13:20 – 14:20	Lunch	
CONTROVERSIES IN TREATMENT		
<i>Session Moderators:</i>		
14:20 – 14:40	Autoantibodies in C3G- are they pathogenic and do they inform diagnosis treatment strategies	Veronique Fremeaux-Bacchi
14:40 – 15:00	Which complement pathway to target in IgAN?	Dana Rizk
15:00 – 15:15	Q&A	
15:15 – 15:35	IC-MPGN and C3G - are they the same and should we treat them the same?	Marina Vivarelli



15:35 – 15:55	IgA nephropathy and IgA vasculitis - are they the same and should we treat them the same?	Evangeline Pillebout
15:55 – 16:15	What does complement therapy offer beyond control of glomerular inflammation?	Steve Sacks
16:15 – 16:35	Q&A	
16:35 – 17:00	<i>Coffee Break</i>	
COMBINING COMPLEMENT INHIBITORS WITH OTHER IMMUNOMODULATORY THERAPIES		
<i>Session Moderators:</i>		
17:00 – 17:20	Complement inhibitors with B cell modulation/depletion in IgAN	Richard Lafayette
17:20 – 17:40	C3G with monoclonal gammopathies - how should we treat	Frank Bridoux
17:40 – 17:55	Q&A	
17:55 – 18:00	Close for the day	

Sunday, 4 May 2025

Time	Talk Topic	Speaker
8:30 – 8:35	Welcome for the day	David Kavanagh and Jonathan Barratt
UNMET NEEDS IN C3G AND IgAN		
<i>Session Moderators:</i>		
8:35 – 8:55	C3G in children-how does complement inhibition fit in?	Alison Ma
8:55 – 9:15	IgA vasculitis and IgA nephropathy in children - how does complement inhibition fit in?	Louise Oni
9:15 – 9:35	IC-MPGN, C3G and IgAN diagnosis and management in low resource settings	Hernan Trimarchi
9:35 – 9:55	Q&A	
WHEN SHOULD COMPLEMENT THERAPIES BE STARTED AND STOPPED IN C3G AND IgAN?		
<i>Session Moderators:</i>		
9:55 – 10:15	C3G	Edwin Wong
10:15 – 10:35	IgAN	Heather Reich
10:35 – 10:50	Q&A	
10:50 – 11:10	<i>Coffee Break</i>	
WHAT MORE DO WE NEED/NEED TO KNOW BEFORE COMPLEMENT THERAPEUTICS ENTER ROUTINE CLINICAL PRACTICE IN C3G & IgAN?		
<i>Session Moderators:</i>		
11:10 – 11:30	Where do complement therapeutics fit into the current therapeutic landscape in IgAN?	Brad Rovin
11:30 – 11:50	Where do complement therapeutics fit into the current therapeutic landscape in C3G and IC-MPGN?	Fadi Fakhouri
11:50 – 12:05	Q&A	
12:05 – 13:00	<i>Lunch</i>	



TRANSPLANTATION		
<i>Session Moderators:</i>		
13:00 – 13:20	Current challenges in recurrent post-transplant C3G	Carla Nester
13:20 – 13:40	Current challenges in recurrent post-transplant IgAN	Sapna Shah
13:40 – 13:55	Discussion	
REGIONAL VARIATIONS IN IgAN: EAST VS. WEST		
<i>Session Moderators:</i>		
13:55 – 14:15	The East Asian Experience	Hong Zhang
14:15 – 14:35	The Southern Asian Experience	Suceena Alexander
14:35 – 14:55	The Caucasian Experience	Chee Kay Cheung
14:55 – 15:15	Discussion	
15:15 - 15:30	Close	David Kavanagh and Jonathan Barratt
15:30 – 16:00	<i>Coffee</i>	

This forum is supported by Alexion, Novartis, Sobi, Roche, Vera Therapeutics and Apellis.